Disseminated intravascular coagulation in the newborn
Disseminated intravascular coagulation (DIC) is an acquired bleeding syndrome caused by multiple causes and occurring in many disease processes. Its characteristics are that under the action of certain pathogenic factors, the coagulation system of the body is activated, the coagulation process is accelerated, fibrin deposition and platelet aggregation occur in the microcirculation, leading to extensive microthrombosis in the blood vessels. Due to the consumption of coagulation factors, extensive bleeding occurs. Due to the extensive formation of microthrombosis in the microcirculation, tissue ischemia and hypoxia occur, affecting the function of important organs and even causing organic changes. Newborns have a high incidence of DIC because they are susceptible to serious diseases. The main clinical manifestations are extensive skin, mucosal and visceral bleeding, decreased blood pressure, shock and embolism symptoms.
Related Drugs
Human prothrombin complex
Indication: This product is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiency including: 1. Coagulation factor II, VII, IX, and X deficiency including hemophilia B; 2. Anticoagulant overdose and vitamin K deficiency; 3. Coagulation mechanism disorders caused by liver disease; 4. Patients who are scheduled to undergo surgery due to prolonged prothrombin time due to various reasons; 5. Treatment of bleeding symptoms in patients with hemophilia A who have developed factor VIII inhibitors; 6. Reversal of bleeding induced by coumarin anticoagulants.
Manufacturer:
Hualan Biological Engineering,Inc.